Immix Biopharma, Inc. (IMMX)
| Market Cap | 639.98M +970.3% |
| Revenue (ttm) | n/a |
| Net Income | -34.98M |
| EPS | -0.89 |
| Shares Out | 69.79M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,101,527 |
| Open | 8.86 |
| Previous Close | 8.84 |
| Day's Range | 8.67 - 9.77 |
| 52-Week Range | 1.87 - 11.61 |
| Beta | 0.12 |
| Analysts | Buy |
| Price Target | 17.56 (+91.49%) |
| Earnings Date | May 7, 2026 |
About IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for IMMX stock is "Buy." The 12-month stock price target is $17.56, which is an increase of 91.49% from the latest price.
News
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” ...
Immix Biopharma price target raised to $20 from $15 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Immix Biopharma (IMMX) to $20 from $15 and keeps a Buy rating on the shares. The company announced that…
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
LOS ANGELES, May 21, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the pricing of an underwritten r...
Immix Biopharma’s NXC-201 reaches 95% complete response rate in AL amyloidosis
Immix Biopharma (IMMX) announced that all four relapsed/refractory AL Amyloidosis MRD-negative patients presented at ASH 2025 have converted to complete response – CR -. The NEXICART-2 CR rate is now…
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) – – CR rate now 95% (19 of 20 patients) – – All CRs reached within 1 year of follow-up post-d...
Immix Biopharma Quarterly report: Q1 2026
Immix Biopharma has published its Q1 2026 quarterly earnings report on May 7, 2026.
Immix Biopharma Slides: Corporate presentation
Immix Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on April 30, 2026.
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that...
Immix Biopharma Proxy statement: Proxy filing
Immix Biopharma filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Immix Biopharma Proxy statement: Proxy filing
Immix Biopharma filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon
Immix Biopharma (IMMX) announced that NEXICART-2 enrollment is complete, meeting company guidance, with topline results expected in Q3, followed by BLA submission and planned commercial launch. In add...
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
– Full enrollment of BLA-enabling trial complete, per prior guidance – – Topline NEXICART-2 Results Expected Q3 2026, followed by BLA submission and planned commercial launch – – Onboarded Chief Medic...
Immix Biopharma price target raised to $15 from $14 at Mizuho
Mizuho raised the firm’s price target on Immix Biopharma (IMMX) to $15 from $14 and keeps an Outperform rating on the shares. The firm cites the company’s improved cash position…
Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Immix Biopharma (IMMX) to $15 from $12 and keeps a Buy rating on the shares following the Q4 results. The firm expects…
Immix Biopharma Annual report: Q4 2025
Immix Biopharma has published its Q4 2025 annual report on March 25, 2026.
Immix Biopharma initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Immix Biopharma (IMMX) with an Overweight rating and $20 price target The company is developing NXC-201, a BCMA-directed CAR-T therapy for relapsed/refractory AL a...
Immix Biopharma initiated with an Outperform at Citizens
Citizens initiated coverage of Immix Biopharma (IMMX) with an Outperform rating and $23 price target The firm says the company’s NXC-201 has demonstrated “compelling” clinical data in terms of respons...
Immix Biopharma Slides: Corporate presentation
Immix Biopharma has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Immix Biopharma to Participate in Upcoming Investor Conferences
LOS ANGELES, CA, March 03, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), the global leader in relapsed/refractory AL Amyloidosis, today announced that...
Immix Biopharma initiated with an Outperform at Mizuho
Mizuho analyst Graig Suvannavejh initiated coverage of Immix Biopharma (IMMX) with an Outperform rating and $14 price target which implies 108% upside potential. With no approved therapies for refract...
Immix Biopharma receives FDA breakthrough therapy designation for NXC-201
Immix Biopharma (IMMX) announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to NXC-201 for the treatment of relapsed/refractory AL Amyloidosis. The FDA Bre...
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
– Breakthrough Therapy Designation granted to NXC-201 based on positive NEXICART-2 Phase 2 interim clinical results, presented at the American Society of Hematology (ASH) 2025 annual meeting –
Immix Biopharma files $750M mixed securities shelf
17:29 EST Immix Biopharma (IMMX) files $750M mixed securities shelf
Immix Biopharma Registration statement: Registration Filing
Immix Biopharma filed a registration statement on January 9, 2026, providing details about a securities offering with the SEC.
Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – LOS ANGELES, CA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”...